S'abonner

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial - 29/09/17

Doi : 10.1016/S1470-2045(17)30576-4 
Hagop M Kantarjian, ProfMD a, , , Gail J Roboz, ProfMD b, , Patricia L Kropf, MD c, Karen W L Yee, MD d, Casey L O’Connell, MD e, Raoul Tibes, MD f, g, Katherine J Walsh, MD h, Nikolai A Podoltsev, MD i, Elizabeth A Griffiths, MD j, Elias Jabbour, MD a, Guillermo Garcia-Manero, ProfMD a, David Rizzieri, ProfMD k, Wendy Stock, ProfMD l, Michael R Savona, MD m, Todd L Rosenblat, MD n, Jesus G Berdeja, MD o, Farhad Ravandi, ProfMD a, Edwin P Rock, MD p, Yong Hao, MD p, Mohammad Azab, MD p, Jean-Pierre J Issa, ProfMD q
a University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA 
b Weill Cornell Medicine, Division of Hematology and Oncology, the New York Presbyterian Hospital, New York, NY, USA 
c Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA, USA 
d Princess Margaret Cancer Centre, Toronto, ON, Canada 
e USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA 
f Mayo Clinic Arizona, Scottsdale, AZ, USA 
g Department of Internal Medicine II/Division of Hematology and Medical Oncology, University Medical Center, Würzburg, Germany 
h Ohio State University, James Cancer Hospital, Wexner Medical Center, Columbus, OH, USA 
i Yale University School of Medicine, Hematology Division, New Haven, CT, USA 
j Roswell Park Cancer Institute, Buffalo, NY, USA 
k Duke University Medical Center, Durham, NC, USA 
l University of Chicago, MC2115, Chicago, IL, USA 
m Vanderbilt University Medical Center, Division of Hematology and Oncology, Nashville, TN, USA 
n New York-Presbyterian/Columbia University Medical Center, New York, NY, USA 
o Sarah Cannon Research Institute, Nashville, TN, USA 
p Astex Pharmaceuticals, Pleasanton, CA, USA 
q Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia PA, USA 

* Correspondence to: Prof Hagop M Kantarjian, University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, 77030, USA University of Texas MD Anderson Cancer Center Department of Leukemia Houston TX 77030 USA

Summary

Background

The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short half-lives and suboptimal bone marrow exposure of the drugs. Guadecitabine, a next-generation hypomethylating drug, has a longer half-life and exposure than its active metabolite decitabine. A phase 1 study established 60 mg/m2 guadecitabine for 5 days as an effective treatment schedule. In this phase 2 study, we aimed to assess the safety and activity of two doses and schedules of guadecitabine in older (≥65 years) patients with treatment-naive acute myeloid leukaemia who were not candidates for intensive chemotherapy.

Methods

We did a multicentre, randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naive acute myeloid leukaemia, relapsed or refractory acute myeloid leukaemia, and myelodysplastic syndromes; here we report the phase 2 results from the cohort of treatment-naive patients with acute myeloid leukaemia. We included patients aged at least 65 years from 14 US medical centres (hospitals and specialist cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1) using a computer algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m2 on days 1–5 (5-day schedule) of a 28-day treatment cycle. Treatment allocation was not masked. We also assigned additional patients to guadecitabine 60 mg/m2 in a 10-day schedule in a 28-day treatment cycle after a protocol amendment. The primary endpoint was composite complete response (complete response, complete response with incomplete platelet recovery, or complete response with incomplete neutrophil recovery regardless of platelets). Response was assessed in all patients (as-treated) who received at least one dose of guadecitabine. We present the final analysis, although at the time of the database lock, 15 patients were still in follow-up for overall survival. This study is registered with ClinicalTrials.gov, number NCT01261312.

Findings

Between Aug 24, 2012, and Sept 15, 2014, 107 patients were enrolled: 54 on the 5-day schedule (26 randomly assigned to 60 mg/m2 and 28 to 90 mg/m2) and 53 were assigned to the 10-day schedule. Median age was 77 years (range 62–92), and median follow-up was 953 days (IQR 721–1040). All treated patients were assessable for a response. The number of patients who achieved a composite complete response did not differ between dose groups or schedules (13 [54%, 95% CI 32·8–74·4] with 60 mg/m2 on the 5-day schedule; 16 [59%; 38·8–77·6] with 90 mg/m2 on the 5-day schedule; and 26 [50%, 35·8–64·2] with 60 mg/m2 on the 10-day schedule). The most frequent grade 3 or worse adverse events, regardless of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-day schedule vs 36 [69%] of 52 patients on the 10-day schedule), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20 [39%] vs 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%] vs 14 [27%]). The most common serious adverse events, regardless of relationship to treatment, for the 5-day and 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (14 [27%] vs 16 [31%]), and sepsis (eight [16%] vs 14 [27%]). 23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all in the 10-day cohort).

Interpretation

More than half of older treatment-naive patients with acute myeloid leukaemia achieved a composite complete response with guadecitabine at all drug doses and schedules investigated, with tolerable toxicity. The recommended guadecitabine regimen for this population is 60 mg/m2 in a 5-day schedule. A phase 3 study in this patient population is ongoing (NCT02348489) to assess guadecitabine 60 mg/m2 in a 5-day schedule versus standard of care.

Funding

Astex Pharmaceuticals and Stand Up To Cancer.

Le texte complet de cet article est disponible en PDF.

Plan


© 2017  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 10

P. 1317-1326 - octobre 2017 Retour au numéro
Article précédent Article précédent
  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
  • David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E Johnson
| Article suivant Article suivant
  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
  • Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua, Wee-Joo Chng, Albert Oriol, Robert Z Orlowski, Heinz Ludwig, Thierry Facon, Roman Hajek, Katja Weisel, Vania Hungria, Leonard Minuk, Shibao Feng, Anita Zahlten-Kumeli, Amy S Kimball, Philippe Moreau

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.